ArticleCommunications medicine2026

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial.

Blair V Landon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.